Literature DB >> 22382456

Newer is not always better: all antihypertensive medications do not equally reduce cardiovascular risk.

Gerald W Smetana.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22382456      PMCID： PMC3358392          DOI： 10.1007/s11606-012-2020-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  20 in total

1.  Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  F H Messerli
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

2.  Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  L Lasagna
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 3.  Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Authors:  Benjamin J Powers; Remy R Coeytaux; Rowena J Dolor; Vic Hasselblad; Uptal D Patel; William S Yancy; Rebecca N Gray; R Julian Irvine; Amy S Kendrick; Gillian D Sanders
Journal:  J Gen Intern Med       Date:  2011-12-07       Impact factor: 5.128

Review 4.  Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Authors:  Lars Hjalmar Lindholm; Bo Carlberg; Ola Samuelsson
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 5.  Beta-blockers for hypertension.

Authors:  C S Wiysonge; H Bradley; B M Mayosi; R Maroney; A Mbewu; L H Opie; J Volmink
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 6.  How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.

Authors:  Hazel A Bradley; Charles Shey Wiysonge; Jimmy A Volmink; Bongani M Mayosi; Lionel H Opie
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

7.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272
View more
  2 in total

1.  Triamterene in the Treatment of Hypertension: More Than Just Potassium Sparing?

Authors:  Gerald W Smetana
Journal:  J Gen Intern Med       Date:  2016-01       Impact factor: 5.128

2.  ACE inhibitors versus ARBs versus DRIs: a systematic update.

Authors:  Jeff Kohlwes
Journal:  J Gen Intern Med       Date:  2012-12       Impact factor: 5.128
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.